Neuroprotective Effects of Liraglutide for Stroke Model of Rats
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
The number of diabetes mellitus (DM) patients is increasing, and stroke is deeply associated with DM. Recently, neuroprotective effects of glucagon-like peptide-1 (GLP-1) are reported. In this study, we explored whether liraglutide, a GLP-1 analogue exerts therapeutic effects on a rat stroke model. Wistar rats received occlusion of the middle cerebral artery for 90 min. At one hour after reperfusion, liraglutide or saline was administered intraperitoneally. Modified Bederson’s test was performed at 1 and 24 h and, subsequently, rats were euthanized for histological investigation. Peripheral blood was obtained for measurement of blood glucose level and evaluation of oxidative stress. Brain tissues were collected to evaluate the level of vascular endothelial growth factor (VEGF). The behavioral scores of liraglutide-treated rats were significantly better than those of control rats. Infarct volumes of liraglutide-treated rats at were reduced, compared with those of control rats. The level of derivatives of reactive oxygen metabolite was lower in liraglutide-treated rats. VEGF level of liraglutide-treated rats in the cortex, but not in the striatum significantly increased, compared to that of control rats. In conclusion, this is the first study to demonstrate neuroprotective effects of liraglutide on cerebral ischemia through anti-oxidative effects and VEGF upregulation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similarly, Sato et al. [66] demonstrated upregulation of VEGF in the cerebral cortex of liraglutide-treated rats subjected to MCAO; however, this was not seen within the striatum [66].”
From Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms (2022) · cites this paper as [66]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bederson, J. B., Pitts, L. H., Tsuji, M., Nishimura, M. C., Davis, R. L., & Bartkowski, H. (1986) · Stroke · doi:10.1161/01.str.17.3.472 · Cited by 2,681 · cited 1×
“table; grade 2: decreased resistance to lateral push (and forelimb flexion) without circling; grade 3: same behavior as grade 2, with circling [28,29].”
BackgroundBuse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
McClean, P. L., Parthsarathy, V., Faivre, E., & Hölscher, C. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.0529-11.2011 · Cited by 698 · cited 3×
“Moreover, anti-inflammatory effects of liraglutide might have also influenced the results of this study, as shown in previous Alzheimer’s disease research [10].”
BackgroundResultLi, Y., Perry, T., Kindy, M. S., Harvey, B. K., Tweedie, D., Holloway, H. W., Powers, K., Shen, H., Egan, J. M., Sambamurti, K., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806720106 · Cited by 589 · cited 1×
“disease mouse model, induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), which might also suggest that therapeutic effects of exenatide were strongly related to anti-oxidative effects [8].”
BackgroundHunter, K., & Hölscher, C. (2012) · BMC Neuroscience · doi:10.1186/1471-2202-13-33 · Cited by 504 · cited 1×
“Furthermore, lixisenatide, a newly developed GLP-1 analogue exerted stronger neurogeneic effects than liraglutide on Alzheimer’s disease rodent model, although both agents breached the blood brain barrier and were bioavailable in the brain with subsequent neurogeneic effects [20].”
BackgroundHamilton, A., Patterson, S., Porter, D., Gault, V. A., & Holscher, C. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22565 · Cited by 210 · cited 1×
“In several studies, neurogeneic effects of liraglutide were shown, in that the administration of liraglutide, as well as exenatide, resulted in enhanced proliferation of progenitor cells with a subsequent increase in young neurons in the dentate gyrus of high-fat-diet-fed mice [18] and Alzheimer’s disease mouse model…”
BackgroundBorlongan, C. V., Kaneko, Y., Maki, M., Yu, S.-J., Ali, M., Allickson, J. G., Sanberg, C. D., Kuzmin-Nichols, N., & Sanberg, P. R. (2010) · Stem Cells and Development · doi:10.1089/scd.2009.0340 · Cited by 205 · cited 1×
“Further studies are needed to explore the expression of other neurotrophic factors to fully recognize the therapeutic potential of liraglutide, in view of accumulating evidence that neurohumoral factors secreted from various cells are key to the neuroprotective and neurorestorative effects of cell-based therapies for…”
BackgroundSelf-citationTeramoto, S., Miyamoto, N., Yatomi, K., Tanaka, Y., Oishi, H., Arai, H., Hattori, N., & Urabe, T. (2011) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2011.51 · Cited by 201 · cited 1×
“Several reports demonstrated therapeutic effects of GLP-1 analogue on animal models of diseases in the central nervous system, including stroke, Parkinson’s disease and Alzheimer’s disease, and amyotrophic lateral sclerosis [4–8].”
BackgroundMcClean, P. L., Gault, V. A., Harriott, P., & Hölscher, C. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.12.023 · Cited by 193 · cited 1×
“The same group revealed that administration of liraglutide enhances long term potentiation and suppressed the deterioration of long term potentiation in Alzheimer’s disease rat model [11].”
BackgroundPotential Role of Glucagon-Like Peptide-1 (GLP-1) in Neuroprotection
Hölscher, C. (2012) · CNS Drugs · doi:10.2165/11635890-000000000-00000 · Cited by 191 · cited 1×
“Recently, neuroprotective effects of exenatide, which has 52% homologous amino-acid sequence to GLP-1, were reported in several studies [1,3].”
ResultGlucagon-like peptide 1 and its derivatives in the treatment of diabetes
Nauck, M. A., & Meier, J. J. (2005) · Regulatory Peptides · doi:10.1016/j.regpep.2004.07.014 · Cited by 180 · cited 3×
“Glucagon-like peptide-1 (GLP-1) analogue is recently established as a daily injection drug for type 2 DM, with actions including stimulation of insulin secretion, glucagon suppression, and appetite loss [1].”
BackgroundResultBaba, T., Kameda, M., Yasuhara, T., Morimoto, T., Kondo, A., Shingo, T., Tajiri, N., Wang, F., Miyoshi, Y., Borlongan, C. V., et al. (2009) · Stroke · doi:10.1161/strokeaha.109.563627 · Cited by 140 · cited 3×
“Infarct volumes were calculated as described previously [26,27] and the ratio to the whole brain was statistically analyzed.”
MethodSelf-citationLi, Y., Chigurupati, S., Holloway, H. W., Mughal, M., Tweedie, D., Bruestle, D. A., Mattson, M. P., Wang, Y., Harvey, B. K., Ray, B., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032008 · Cited by 132 · cited 1×
“Several reports demonstrated therapeutic effects of GLP-1 analogue on animal models of diseases in the central nervous system, including stroke, Parkinson’s disease and Alzheimer’s disease, and amyotrophic lateral sclerosis [4–8].”
BackgroundDarsalia, V., Mansouri, S., Ortsäter, H., Olverling, A., Nozadze, N., Kappe, C., Iverfeldt, K., Tracy, L. M., Grankvist, N., Sjöholm, Å., et al. (2012) · Clinical Science · doi:10.1042/cs20110374 · Cited by 130 · cited 1×
“Several reports demonstrated therapeutic effects of GLP-1 analogue on animal models of diseases in the central nervous system, including stroke, Parkinson’s disease and Alzheimer’s disease, and amyotrophic lateral sclerosis [4–8].”
BackgroundParthsarathy, V., & Hölscher, C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058784 · Cited by 130 · cited 1×
“It was also demonstrated in another study that doublecortin-positive neural progenitor cells and NeuN-positive mature neurons increased in the hippocampus [19].”
ResultHyun Lee, C., Yan, B., Yoo, K., Choi, J. H., Kwon, S., Her, S., Sohn, Y., Hwang, I. K., Cho, J. H., Kim, Y., et al. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22596 · Cited by 118 · cited 1×
“Several reports demonstrated therapeutic effects of GLP-1 analogue on animal models of diseases in the central nervous system, including stroke, Parkinson’s disease and Alzheimer’s disease, and amyotrophic lateral sclerosis [4–8].”
BackgroundEgefjord, L., Gejl, M., Møller, A., Brændgaard, H., Gottrup, H., Antropova, O., Møller, N., Poulsen, H. E., GJEDDE, A. H., Brock, B., et al. (2012) · PubMed · Cited by 91
Xiao-Yun, X., Zhao-Hui, M., Ke, C., Hong-Hui, H., & Yan-Hong, X. (2011) · Medical Science Monitor · doi:10.12659/msm.881383 · Cited by 88 · cited 1×
“Recent studies revealed that GLP-1 enhances proliferation and differentiation of endothelial progenitor cells through upregulation of vascular endothelial growth factor [21].”
BackgroundThe Potential Role of Vascular Endothelial Growth Factor in the Central Nervous System
Yasuhara, T., Shingo, T., & Date, I. (2004) · Reviews in the Neurosciences · doi:10.1515/revneuro.2004.15.4.293 · Cited by 85 · cited 1×
“Of note, VEGF exerts neuroprotective, angiogeneic, neurogeneic, and anti-inflammatory effects on various diseases of the central nervous system [22,23].”
BackgroundSelf-citationKameda, M., Shingo, T., Takahashi, K., Muraoka, K., Kurozumi, K., Yasuhara, T., Maruo, T., Tsuboi, T., Uozumi, T., Matsui, T., et al. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05776.x · Cited by 84 · cited 2×
“Infarct volumes were calculated as described previously [26,27] and the ratio to the whole brain was statistically analyzed.”
MethodSelf-citationErdogdu, Ö., Eriksson, L., Xu, H., Sjöholm, Å., Zhang, Q., & Nyström, T. (2013) · Journal of Molecular Endocrinology · doi:10.1530/jme-12-0166 · Cited by 75 · cited 1×
“These findings advance the key role of anti-oxidative signaling pathways in exenatide’s therapeutic benefits [16].”
BackgroundHou, J., Manaenko, A., Hakon, J., Hansen-Schwartz, J., Tang, J., & Zhang, J. H. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.133 · Cited by 57 · cited 1×
“Recently, therapeutic effects of liraglutide on an animal model of intracerebral hemorrhage were shown to be mediated by suppression of neuroinflammation and brain edema [13].”
BackgroundMorimoto, T., Yasuhara, T., Kameda, M., Baba, T., Kuramoto, S., Kondo, A., Takahashi, K., Tajiri, N., Wang, F., Meng, J., et al. (2011) · Cell Transplantation · doi:10.3727/096368910x544915 · Cited by 56 · cited 1×
“Enhancement of endogenous neurogenesis might be a promising strategy of regenerative medicine for diseases in the central nervous system [17].”
BackgroundSelf-citationJimenez‐Feltström, J., Lundquist, I., & Salehi, A. A. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-1013-4 · Cited by 54 · cited 2×
“Previously, a few reports demonstrated anti-oxidative effects of exenatide and GLP-1 on pancreatic islet cells [14,15].”
BackgroundExendin-4 Protects Hypoxic Islets From Oxidative Stress and Improves Islet Transplantation Outcome
Padmasekar, M., Lingwal, N., Samikannu, B., Chen, C., Sauer, H., & Linn, T. (2013) · Endocrinology · doi:10.1210/en.2012-1983 · Cited by 53 · cited 2×
“Previously, a few reports demonstrated anti-oxidative effects of exenatide and GLP-1 on pancreatic islet cells [14,15].”
BackgroundExendin-4 improved rat cortical neuron survival under oxygen/glucose deprivation through PKA pathway
Wang, M., Huang, Y., Zhang, G.-P., Mao, L., Xia, Y., Mei, Y.-W., & Hu, B. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.09.025 · Cited by 51 · cited 1×
“Exenatide was mainly used in those studies and neurons were protected against oxygen and glucose deprivation at least partly through the protein kinase A (PKA) pathway in vitro [9].”
MethodPost-treatment with amphetamine enhances reinnervation of the ipsilateral side cortex in stroke rats
Liu, H.-S., Shen, H., Harvey, B. K., Castillo, P., Lu, H., Yang, Y., & Wang, Y. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2011.02.049 · Cited by 49 · cited 1×
“table; grade 2: decreased resistance to lateral push (and forelimb flexion) without circling; grade 3: same behavior as grade 2, with circling [28,29].”
BackgroundYasuhara, T., & Date, I. (2007) · Cell Transplantation · doi:10.3727/000000007783464632 · Cited by 49 · cited 1×
“Of note, VEGF exerts neuroprotective, angiogeneic, neurogeneic, and anti-inflammatory effects on various diseases of the central nervous system [22,23].”
BackgroundSelf-citationMorishita, Y., Hanawa, S., Chinda, J., Iimura, O., Tsunematsu, S., & Kusano, E. (2010) · Hypertension Research · doi:10.1038/hr.2010.238 · Cited by 44 · cited 1×
“08 mg/dL of H2O2) [30].”
Liraglutide prevents diabetes progression in prediabetic OLETF rats
Guo, N., Sun, J., Chen, H., Zhang, H., Zhang, Z., & Cai, D. (2013) · Endocrine Journal · doi:10.1507/endocrj.ej12-0094 · Cited by 29 · cited 1×
“The dose of liraglutide and timing of administration used in our study was determined by previous studies on DM [25] and our preliminary study (data not shown).”
Method
Cited by
Ahmad, E., Lim, S., Lamptey, R., Webb, D. R., & Davies, M. J. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01655-5 · Cited by 1,120
GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
Zhao, X., Wang, M., Wen, Z., Lu, Z., Cui, L., Fu, C., Xue, H., Liu, Y., & Zhang, Y. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.721135 · Cited by 463
“Sato et al. found that intraperitoneal injection of liraglutide 2.5 h after stroke induced neuroprotection in rats, which was related to the upregulation of vascular endothelial growth factor (VEGF) (86).”
BackgroundInfluentialThe role of type 2 diabetes in neurodegeneration
Verdile, G., Fuller, S. J., & Martins, R. N. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.04.008 · Cited by 272
Liu, W., Jalewa, J., Sharma, M., Li, G., Li, L., & Hölscher, C. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.06.054 · Cited by 246
Zhu, H., Zhang, Y., Shi, Z., Lu, D., Li, T., Ding, Y., Ruan, Y., & Xu, A. (2016) · Scientific Reports · doi:10.1038/srep26859 · Cited by 183
Metadata
- Authors
- Sato, K., Kameda, M., Yasuhara, T., Agari, T., Baba, T., Wang, F., Shinko, A., Wakamori, T., Toyoshima, A., Takeuchi, H., Sasaki, T., Sasada, S., Kondo, A., Borlongan, C., Matsumae, M., & Date, I.
- Affiliations
- Tokai University (JP)
- Okayama University (JP)
- University of Kochi (JP)
- Department of Neurosurgery, University of South Florida College Medicine, Tampa, FL 12901, USA
- Corresponding author
- Yasuhara, Takao
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2013-10-30
- Volume
- 14
- Issue
- 11
- Pages
- 21513-21524
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC3856019
- OpenAlex
- W2094706071
- Cited by
- 120
- References
- 30
- Citations by year
- 2026: 2 · 2025: 7 · 2024: 7 · 2023: 5 · 2022: 10 · 2021: 6 · 2020: 11 · 2019: 13 · 2018: 18 · 2017: 10 · 2016: 10 · 2015: 17 · 2014: 4
- FWCI
- 5.80
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Ministry of Education, Culture, Sports, Science and Technology
- Japan Society for the Promotion of Science (23791602, 23390349)
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroprotection in Cerebral Ischemia
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- liraglutide, neuroprotection, stroke, cerebral ischemia, middle cerebral artery occlusion, GLP-1 analogues, oxidative stress, reactive oxygen species, vascular endothelial growth factor, infarct size, diabetes mellitus, reperfusion
- MeSH terms
- Liraglutide, Animals, Blood Glucose, Disease Models, Animal, Humans, Oxidative Stress, Neuroprotective Agents, Infarction, Middle Cerebral Artery, Stroke, Vascular Endothelial Growth Factor A, Diabetes Complications, Rats, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.